Table 1 Patient clinicopathological characteristics
From: Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
Sample ID | Age | Pre-treatment PSA (ng/ml) | Pathological stages | Gleason score | Risk group based on NCCN guidelines |
|---|---|---|---|---|---|
B15 | 67 | 5.4 | cT2a cN0 cM0 | 3 + 4 | IR |
B16 | 76 | 15.8 | cT2a cN0 cM0 | 4 + 3 | IR |
B17 | 78 | 6.3 | cT2b cN0 cM0 | 3 + 4 | IR |
B03 | 82 | 24.4 | cT1c cN0 cM0 | 8 | HR |
B60 | 68 | 17.6 | cT2a cN0 M0 | 3 + 4 | IR |
C73 | 66 | 0.9 | pT2a pN0 M0 | 3 + 4 | IR |
B09 | 71 | 13.30 | cT3a cN0 M0 | 4 + 5 | HR |
C05 | 74 | 0.40 | pT3 pN0 M0 | 3 + 4 | HR |
C12 | 67 | 0.20 | pT3a pN0 M0 | 3 + 4 | HR |
B71 | 54 | 7.2 | cT1c cN0 cM0 | 3 + 3 | IR |
C59 | 73 | 0.8 | pT3a pN0 cM0 | 4 + 4 | HR |